electroCore Announces Record Second Quarter 2022 Financial Results
Record second quarter 2022 net sales of
Company to host a conference call and webcast today,
Second Quarter 2022 and Recent Highlights
- Posted revenue of
$2.2 million, representing an increase of approximately 70% over second quarter 2021 and 14% sequentially;
- Net cash used in operating activities was
$3.2 millionduring the second quarter 2022 leaving approximately $26.6 millionof cash and cash equivalents at June 30, 2022;
- Announced gammaCore™ non-invasive vagus nerve stimulator (nVNS) selected for
Department of Defense Biotech Optimized for Operational Solutions and Tactics(BOOST) program; and
- Announced exclusive license agreement with Teijin Limited (Teijin) for
Second Quarter 2022 Financial Results
For the quarter ended
|Channel||Three months ended
||Three months ended
||% Change||Three months ended
|United States Commercial||$||501,000||$||333,000||50.5||%||$||104,000||381.7||%|
|Teijin License Revenue||$||48,000||$||-||N/A||$||-||N/A|
Gross profit for the second quarter of 2022 was
The company's evolving commercial strategy has resulted in the launch of cash payment models under which it licenses certain starter devices. The cost of the licensed starter device is being recognized as cost of goods sold over the estimated useful life of the starter device versus expensing the cost of goods at the time of sale. Moreover, in recent quarters, the company has sold an increasing amount of longer duration therapy, resulting in a higher average selling price. These factors, including Teijin license revenue with no associated cost of goods and favorable absorption of labor and overhead costs due to an increase in the number of units sold, contributed to the increase in gross margin.
Total operating expenses in the second quarter of 2022 were approximately
Research and development expense in the second quarter of 2022 was
Selling, general and administrative expense in the second quarter of 2022 was
GAAP net loss in the second quarter of 2022 was
Adjusted EBITDA net loss in the second quarter of 2022 was
The company defines adjusted EBITDA net loss as GAAP net loss as adjusted to exclude non-operating gains and losses, depreciation and amortization, stock-based compensation expense, legal fees associated with stockholders’ litigation, benefit from income taxes, and gain on extinguishment of debt. A reconciliation of GAAP net loss to non-GAAP adjusted EBITDA net loss has been provided in the financial statement tables included in this press release.
Net cash used in operating activities in the quarter ended
Cash, cash equivalents and restricted cash at
Third Quarter 2022 Outlook
For the third quarter of 2022, the Company expects net revenue to be approximately Q2 2022 levels and net cash usage to be between
Webcast and Conference Call Information
electroCore’s management team will host a conference call today,
Investors interested in listening to the conference call or webcast may do so by dialing 877-269-7756 for domestic callers or 201-689-7817 for international callers, using Conference ID: 13731362, or by connecting to the electroCore Earnings Webcast. An archived webcast of the event will be available on the “Investors” section of the company’s website at: www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
For more information, please visit gammaCore.com.
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans (including with respect to enrollment in ongoing studies such as the BOOST program); its expected revenue and net cash used in operating activities for the third quarter of 2022; its pipeline, future product development and potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including online, e-commerce, direct-to-consumer channels, telehealth portal, and cash pay initiatives; the issuance of
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
|Three Months Ended
||Six Months Ended
|Cost of goods sold||358||374||718||738|
|Research and development||1,341||825||2,275||1,324|
|Selling, general and administrative||6,278||5,272||12,464||10,997|
|Total operating expenses||7,619||6,097||14,739||12,321|
|Loss from operations||(5,820||)||(5,202||)||(11,401||)||(10,586||)|
|Other (income) expense|
|Gain on extinguishment of debt||—||(1,422||)||—||(1,422||)|
|Interest and other income||(38||)||(1||)||(42||)||(1||)|
|Total other (income) expense||(38||)||(1,423||)||(37||)||(1,423||)|
|Loss before income taxes||(5,782||)||(3,779||)||(11,364||)||(9,163||)|
|Benefit from income taxes||445||885||445||885|
|Net loss per share of common stock - Basic and Diluted||$||(0.08||)||$||(0.06||)||$||(0.15||)||$||(0.17||)|
|Weighted average number of common shares outstanding - Basic and Diluted||70,816||48,520||70,744||48,089|
Condensed Consolidated Balance Sheet Information
|Cash and cash equivalents||$||26,330||$||34,689|
(Unaudited) Use of Non-GAAP Financial Measure
The company is presenting adjusted EBITDA net loss because it believes this measure is a useful indicator of its operating performance. electroCore management uses this non-GAAP measure principally as a measure of the company’s core operating performance and believes that this measure is useful to investors because it is frequently used by the financial community, investors, and other interested parties to evaluate companies in the company’s industry. The company also believes that this measure is useful to its management and investors as a measure of comparative operating performance from period to period. Additionally, the company believes its use of non-GAAP adjusted EBITDA net loss from operations facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by gains and charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges such as restructuring expenses.
The company defines adjusted EBITDA net loss as GAAP net loss, adjusting to exclude non-operating gains and losses, depreciation and amortization, stock-compensation expense, legal fees associated with stockholders’ litigation, interest and other income/expense, benefit from income taxes, and gain on extinguishment of debt.
Following is a reconciliation of GAAP net loss to Non-GAAP adjusted EBITDA net loss (in thousands):
|Three Months ended
||Six Months ended June 30,|
|GAAP net loss||$||(5,337||)||$||(2,894||)||$||(10,919||)||$||(8,278||)|
|Depreciation and amortization||141||95||247||191|
|Legal fees associated with stockholders' litigation||71||166||132||317|
|Interest and other (income) expense||(38||)||(1||)||(37||)||(1||)|
|Benefit from income taxes||(445||)||(885||)||(445||)||(885||)|
|Gain on extinguishment of debt||—||(1,422||)||—||(1,422||)|
|Adjusted EBITDA net loss||$||(4,856||)||$||(4,103||)||$||(9,493||)||$||(8,298||)|
The company’s use of a non-GAAP measure has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of its results as reported under GAAP. Some of these limitations are: the non-GAAP measure does not reflect interest or tax payments that may represent a reduction in cash available; although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and the non-GAAP measure does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; the non-GAAP measure does not reflect the potentially dilutive impact of equity-based compensation; and the non-GAAP measure does not reflect changes in, or cash requirements for, working capital needs; other companies, including companies in electroCore’s industry, may calculate adjusted EBITDA net loss differently, which reduces its usefulness as a comparative measure.
Because of these and other limitations, you should consider the non-GAAP measure together with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and other GAAP results. A reconciliation of GAAP net loss to non-GAAP adjusted EBITDA net loss has been provided in the preceding financial statements table of this press release.